Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1–specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature

Saito, Shoji; Yanagisawa, Ryu; Yoshikawa, Kentaro; Higuchi, Yumiko; Koya, Terutsugu; Yoshizawa, Kiyoshi; Tanaka, Miyuki; Sakashita, Kazuo; Kobayashi, Takashi; Kurata, Tadao; Hirabayashi, Koichi; Nakazawa, Yozo; Shiohara, Masaaki; Yonemitsu, Yoshikazu; Okamoto, Masato; Sugiyama, Haruo; Koike, Kenichi; Shimodaira, Shigetaka

doi:10.1016/j.jcyt.2014.10.003

Cited by 40 publications

(36 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This approach was assessed as effective in several patients with posttransplant-relapsed AML or ALL. The GvHD was assessed as mild and no serious adverse events were reported [49][50][51]. Ongoing clinical trials are developed to assess WT1 dendritic cell vaccines in larger groups of patients.…”

Section: Unique Aspects Of Anti-cancer Drug Development 76mentioning

confidence: 99%

Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?

Barełkowska¹,

Derwich²

2017

Unique Aspects of Anti-Cancer Drug Development

View full text Add to dashboard Cite

The last decade became the renaissance for investigating and exploring the potential role of immunotherapy in pediatric acute leukemia (AL). It is beyond question that there is an interaction between innate immune system and hematological malignancy. Leukemia cells inhibit the host immune response according to multiple mechanisms, but exploiting the innate immune system mechanisms can overcome the resistance to the conventional treatment. What is the role of immunotherapy in pediatric AL treatment? Does it have the potential to substitute or combine the standard chemotherapy? What is the best possible timing to take advantage of immune interventions? This review is considered to follow through the possible treatment options including their foundation, strong and weak points, but also information about possible implementation into the clinical practice.

show abstract

Section: Unique Aspects Of Anti-cancer Drug Development 76mentioning

confidence: 99%

Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?

Barełkowska¹,

Derwich²

2017

Unique Aspects of Anti-Cancer Drug Development

View full text Add to dashboard Cite

show abstract

“…A single patient with residual active leukemia following haematopoietic stem cell transplant (HSCT) was reported to receive an allogeneic DC vaccine derived from PBMC collected from her stem cell donor. 16 Our group reported a single patient with neuroblastoma whose DC were generated from a cryopreserved, G-CSF mobilized peripheral blood stem cell (PBSC) product, 3 and Nair reported the feasibility of generating DC from cryopreserved autologous PBSC products in patients with medulloblastoma. 17 This group was able to generate phenotypic DC from 3/5 samples and functional DC from 2/5 samples.…”

Section: Source Of Dendritic Cellsmentioning

confidence: 99%

Dendritic cell vaccines: A review of recent developments and their potential pediatric application

Elster

Krishnadas

Lucas

2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

For many cancers the use of conventional chemotherapy has been maximized, and further intensification of chemotherapy generally results in excess toxicity with little long-term benefit for cure. Many tumors become resistant to chemotherapy, making the investigation of novel approaches such as immunotherapy of interest. Because the tumor microenvironment is known to promote immune tolerance and down regulate the body's natural defense mechanisms, modulating the immune system with the use of dendritic cell (DC) therapy is an attractive approach. Thousands of patients with diverse tumor types have been treated with DC vaccines. While antigen specific immune responses have been reported, the duration and magnitude of these responses are typically weak, and objective clinical responses have been limited. DC vaccine generation and administration is a multi-step process with opportunities for improvement in source of DC for vaccine, selection of target antigen, and boosting effector cell response via administration of vaccine adjuvant or concomitant pharmacologic immunomodulation. In this review we will discuss recent developments in each of these areas and highlight elements that could be moved into pediatric clinical trials.

show abstract

“…Five articles described for pancreatic cancer [19][20][21][22][23] , 2 for biliary tract cancer [24,25] , 1 for lung cancer [26] , 1 for ovarian cancer [27] , 1 for pediatric patient with relapsed leukemia [28] , 1 for gastric cancer [29] , 1 for malignant glioma [30] , and 1 for several types of advanced cancers treated with radiation therapy in combination with DC vaccine [31] . Here, we introduce the Vaccell's effects in pancreatic cancer patients in which the analysis has been progressed to most among these cases.…”

Section: Clinical Effects Of the Vaccell Mainly In Pancreatic Cancermentioning

confidence: 99%

Dendritic cell-based vaccine for pancreatic cancer in Japan

Okamoto

Kobayashi

Yonemitsu

et al. 2016

WJGPT

Self Cite

View full text Add to dashboard Cite

Abstract"Vaccell" is a dendritic cell (DC)-based cancer vaccine which has been established in Japan. The DCs play central roles in deciding the direction of host immune reactions as well as antigen presentation. We have demonstrated that DCs treated with a streptococcal immune adjuvant OK-432, produce interleukin-12, induce Th1-dominant state, and elicit anti-tumor effects, more powerful than those treated with the known DCmaturating factors. We therefore decided to mature DCs by the OK-432 for making an effective DC vaccine, Vaccell. The 255 patients with inoperable pancreatic cancer who received standard chemotherapy combined with DC vaccines, were analyzed retrospectively. Survival time of the patients with positive delayed type hypersensitivity (DTH) skin reaction was significantly prolonged as compared with that of the patients with negative DTH. The findings strongly suggest that there may be "Responders" for the DC vaccine in advanced pancreatic cancer patients. We next conducted a smallscale prospective clinical study. In this trial, we pulsed HLA class Ⅱ-restricted WT1 peptide (WT1-Ⅱ) in addition to HLA class Ⅰ-restricted peptide (WT1-Ⅰ) into the DCs. Survival of the patients received WT1-Ⅰ and -Ⅱ pulsed DC vaccine was significantly extended as compared to that of the patients received DCs pulsed with WT1-Ⅰ or WT1-Ⅱ alone. Furthermore, WT1-specific DTH positive patients showed significantly improved the overall survival as well as progressionfree survival as compared to the DTH negative patients. may be associated with a good clinical outcome in advanced pancreatic cancer. We are now planning a pivotal study of the Vaccell in appropriate protocols in Japan.

show abstract

Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1–specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature

Cited by 40 publications

References 13 publications

Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?

Immunotherapy in Pediatric Acute Leukemia: A Novel Magic Bullet or an Illusory Hope?

Dendritic cell vaccines: A review of recent developments and their potential pediatric application

Dendritic cell-based vaccine for pancreatic cancer in Japan

Contact Info

Product

Resources

About